Atossa Therapeutics, Inc.
ATOSAtossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines for oncology, with a primary emphasis on breast cancer and other breast conditions.
Earnings
Next report
Nov 11, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines for oncology, with a primary emphasis on breast cancer and other breast conditions. The company's core value proposition centers on its proprietary (Z)-endoxifen, a selective estrogen receptor modulator and degrader designed to overcome the metabolic limitations of traditional therapies. Their strategy involves advancing clinical programs through internal development and strategic collaborations to address significant unmet medical needs.
A clinical-stage innovator with proprietary patent protection for (Z)-endoxifen through 2038, targeting limitations in current standard-of-care endocrine therapies.
FAQ
- What is Atossa Therapeutics, Inc.'s market cap?
- Atossa Therapeutics, Inc. (ATOS) has a market capitalization of $26.4M and trades on NASDAQ.
- Who are Atossa Therapeutics, Inc.'s competitors?
- Atossa Therapeutics, Inc.'s key competitors include Eli Lilly and Company, Zentalis Pharmaceuticals, Inc. Common Stock, LeonaBio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Where is Atossa Therapeutics, Inc. headquartered?
- Atossa Therapeutics, Inc. is headquartered in United States of America and employs approximately 10 people. It has been publicly traded since 2012.